And I agree with you and others. R-It was a long and expensive trial with amazing results. We, & Amarin have been quagmired since the Du decision. So, all I am saying is any additional positive news has to put us in a better place than we currently sit.
Amarin C-Suite and BOd have benefitted but not the shareholders and I am pissed that they continue to award themselves options and RSU's for NO positive results.
Somehow this drug has to begin it's upward trajectory and any additional good news from Mitigate, Brave, etc. will (should) benefit.
Bring on Denner to move us forward. I don't have a 2-5 year window for this to drag out.
Market Data 
Markets 
AI
